Analysis of Segments and Major Growth Areas in the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

The sodium glucose cotransporter 2 (SGLT2) inhibitors market is on track for significant expansion in the coming years, driven by various advancements and growing medical needs. This market is becoming increasingly relevant not only for diabetes management but also for broader cardiovascular and renal health applications. Let's explore the projected growth, key players, emerging trends, and detailed market breakdown of this dynamic pharmaceutical sector.

Projected Growth and Size of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
The global market for sodium glucose cotransporter 2 inhibitors is anticipated to reach a value of $16.35 billion by 2030. This growth reflects a compound annual growth rate (CAGR) of 8.3% over the forecast period. Several factors contribute to this expansion, including rising awareness of the cardio-renal benefits provided by these drugs, an increasing elderly diabetic population, broader reimbursement policies, ongoing launches of novel medications, and deeper penetration into emerging markets. Key trends shaping the market include a widening scope of use beyond traditional diabetes treatment, higher adoption rates of combination therapies, growth in heart failure indications, enhanced safety profiles, and expanded inclusion in clinical guidelines.

Download a free report of the sodium glucose cotransporter 2 (sglt2) inhibitors market report:
https://www.thebusinessresearchcompany.com/report/sodium-glucose-cotransporter-2-sglt2-inhibitors-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Companies Driving the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
The market features several prominent pharmaceutical firms that dominate the competitive landscape. Some of the major players include Johnson & Johnson Inc., Merck & Co Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Astellas Pharma Inc, Sun Pharmaceutical Industries Ltd, Sumitomo Dainippon Pharma Co Ltd, Taisho Pharmaceutical Holdings Co Ltd, Lupin Limited, Glenmark Pharmaceuticals, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Kissei Pharmaceutical Co Ltd, Kotobuki Pharmaceutical Co Ltd, Lexicon Pharmaceuticals Inc, Novartis AG, Takeda Pharmaceutical Company Limited, Hanmi Pharmaceutical Co Ltd, Chong Kun Dang Pharmaceutical Corp, and Mitsubishi Tanabe Pharma Corporation.

Strategic Partnership Expands Commercial Reach of Sotagliflozin
In October 2024, Viatris Inc., a US-based global healare company, signed an exclusive licensing agreement with Lexicon Pharmaceuticals to commercialize sotagliflozin outside the U.S. and Europe. This partnership is designed to improve patient access to sotagliflozin, enhance diabetes treatment options worldwide, and stimulate innovation in the diabetes therapeutics field. Lexicon Pharmaceuticals, headquartered in the US, focuses on developing novel therapies for metabolic disorders, positioning them as a key innovator in this area.

View the full sodium glucose cotransporter 2 (sglt2) inhibitors market report:
https://www.thebusinessresearchcompany.com/report/sodium-glucose-cotransporter-2-sglt2-inhibitors-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Market Trends Highlight the Shift Toward Dual Inhibitor Therapies
Companies in the SGLT2 inhibitors market are increasingly focusing on dual inhibitor therapies that target both SGLT1 and SGLT2 proteins to improve treatment effectiveness. These dual inhibitors aim to provide better management of blood sugar levels and related cardiovascular complications. For example, in May 2023, Lexicon Pharmaceuticals received FDA approval for sotagliflozin, the first dual SGLT1 and SGLT2 inhibitor, administered once daily. This treatment helps reduce cardiovascular death, hospitalizations from heart failure, and urgent heart failure visits among adults suffering from heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risks. Its mechanism involves lowering renal glucose and sodium reabsorption, which in turn reduces heart workload and sympathetic nervous system activity.

Detailed Segment Analysis of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
This report categorizes the SGLT2 inhibitors market into several important segments:
1) By Type: Invokana, Jardiance, Farxiga or Forxiga, Suglat
2) By Route of Administration: Oral route, Other routes of administration
3) By End User: Hospitals, Homecare settings, Clinics

Further subdivisions include:
- Invokana: Generic Invokana (Canagliflozin) and Branded Invokana
- Jardiance: Generic Jardiance (Empagliflozin) and Branded Jardiance
- Farxiga or Forxiga: Generic Farxiga (Dapagliflozin) and Branded Farxiga
- Suglat: Suglat (Sotagliflozin) for diabetes treatment and Suglat (Sotagliflozin) for heart failure management

These segment insights offer a comprehensive understanding of the market's product landscape, administration preferences, and end-user distribution, highlighting areas of growth and opportunity within the global SGLT2 inhibitors market.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.